In the GRAALL (France/Belgium/Switzerland) phase III trial, CD20+ BCP, ALL patients (CD20 expression >20%) were randomized with a 2×2 design concurrently testing an augmented cyclophosphamide dose; whereas in the randomized MRC (United Kingdom) trial, all BCP ALL patients were randomized to assess the role of the concomitant corticosteroid therapy in upregulating CD20 expression in CD20− patients. This evidence concerns the gene MS4A1 and acute lymphoblastic leukemia.